rfxcel Awarded ISO 9001:2015 Certification
rfxcel, the leader in track and trace solutions for global supply chains announced that it is now ISO 9001:2015 certified for Quality Management Systems.
The certifying organization used by rfxcel examined rfxcel’s commitment to customer service and requests, commitment to quality from upper management, and processes and procedures put in place to ensure the delivery of quality systems. rfxcel demonstrated its long-standing commitment to quality management and processes and was officially certified on November 4, 2018.
“This certification is a testament to rfxcel’s determination and commitment to continually improve as a business, provide our customers with uncompromising experiences, and drive a culture that produces high-quality products and services. Attaining this certification indicates the dedication rfxcel has taken in supporting our customers and exceeding their expectations. Quality is one of our strengths, and it is the reason we are the preferred partner for organizations globally.” – Amit Sewak, rfxcel, Director of Quality Management & Validation.
The scope of the certification included rfxcel’s flagship product rfxcel Traceability System for serialization (rTS). rTS is used by some of the world’s largest pharmaceutical manufacturers, wholesalers, distributors, and dispensers and is being adopted in other industries like Food and Beverage, Consumer Goods, and the Public Sector.
According to ISO, the 9001:2015 certification means that rfxcel demonstrated the seven following quality management principles for rTS:
• QMP 1 Customer Focus
• QMP 2 Leadership
• QMP 3 Engagement of People
• QMP 4 Process Approach
• QMP 5 Continual Improvement
• QMP 6 Evidence-Based Decision Making
• QMP 7 Relationship Management
“Very few if any of our competitors can claim to be ISO 9001:2015 certified. It is a testament to our role as a leader in our industry and our commitment to quality. This certification assures our customers that quality management practices are baked into our systems. Those quality practices and procedures are passed on to our customers through consistent products and services, which brings business benefits like a lower total cost of ownership and predictable outcomes.” – rfxcel, CEO Glenn Abood
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.